John J. Kopchick
Discovered the growth hormone receptor antagonist that became the acromegaly drug pegvisomant (Somavert), and studies how blocking growth hormone signalling extends lifespan in mice
Distinguished Professor & Goll-Ohio Eminent Scholar, Ohio University (since 2012) · Edison Biotechnology Institute, Ohio University (1987–present) · senior scientist, Merck Institute of Therapeutic Research (1982–1986) · postdoctoral fellow, Roche Institute of Molecular Biology (1980–1982) · PhD, University of Texas Graduate School of Biomedical Sciences at MD Anderson (1980)
Portrait: Ohio University
Decades after his accidental early-1990s discovery that a mutated growth hormone (GH) molecule could block rather than activate the GH receptor — work that became the FDA-approved drug pegvisomant — Kopchick's lab is now using the same logic to ask how far blocking GH action can extend life. In List et al. 2026 (LIST2026), his team studied a long-standing line of transgenic mice (kept in the lab since 1991) that express a GH receptor antagonist built on the same G119K mutant chemistry behind pegvisomant, and found it significantly extended both median and maximal lifespan in both sexes. A companion study, Duran-Ortiz et al. 2026 (DUR2026), showed that deleting the GH receptor gene starting only at 12 months of age (adult-onset) still extended healthy lifespan in both sexes.
Kopchick's original discovery happened almost by accident: while trying to engineer a bigger mouse, he instead produced a dwarf mouse. That molecule became Somavert (pegvisomant), still used worldwide to treat acromegaly, generating roughly $100+ million in licensing royalties for Ohio University. He trained at MD Anderson and the Roche Institute before four years at Merck, joining Ohio University in 1987.
He has since built one of the world's most extensive collections of GH-signaling mouse models, holds 17 patents, has published 400+ papers, is a National Academy of Inventors Fellow, and received the Endocrine Society's 2019 Laureate Award for Outstanding Innovation.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2026 | A | Growth Hormone Receptor Antagonism Extends Lifespan LIST2026 Kopchick's own antagonist chemistry — the molecular basis of pegvisomant — is shown for the first time to extend lifespan in mice when expressed transgenically. |
| 2026 | A | Midlife Growth Hormone Receptor Ablation Extends Healthy Lifespan and Induces Sex-Specific Hepatic Transcriptional Changes at Single-Cell Resolution DUR2026 As senior investigator, shows that even adult-onset disruption of GH receptor signaling extends healthy lifespan. |
Co-authors in the Atlas 4
People with a profile here who share at least one study with John J. Kopchick.
ShowHide
- Darlene E. Berryman 2 shared studies Showed that growth hormone reshapes fat tissue in a depot-specific way that links body composition to metabolic aging
- Edward O. List 2 shared studies Carries out mouse studies, in John Kopchick's group, on how disrupting growth hormone receptor signaling extends mammalian lifespan
- Silvana Duran-Ortiz Researcher in John Kopchick's group at Ohio University who studies how switching off growth hormone action, even in middle age, lengthens life in mice
- Yuji Ikeno Pathologist at the Barshop Institute for Longevity and Aging Studies in San Antonio whose examinations of tissues from aged mice help ageing studies tell whether an intervention changes disease, especially cancer, late in life
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.